Previous close | 0.6750 |
Open | 0.6650 |
Bid | 0.6250 x 1566800 |
Ask | 0.6550 x 380500 |
Day's range | 0.6200 - 0.6650 |
52-week range | 0.3125 - 0.8150 |
Volume | |
Avg. volume | 723,028 |
Market cap | 414.254M |
Beta (5Y monthly) | 0.73 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.4600 |
Earnings date | 28 Feb 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | 11 Oct 2004 |
1y target est | 10.10 |
MELBOURNE, Australia and PRINCETON, N.J., April 25, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration, today announced that Dr. Frederic Guerard, Chief Executive Officer (CEO) of Opthea, will present the Company’s clinical-stage pipeline, as well as its innovation agenda, at the OIS Retina
Key Insights Institutions' substantial holdings in Opthea implies that they have significant influence over the...
Brings extensive experience in retinal and ophthalmology diseasesMELBOURNE, Australia and PRINCETON, N.J., April 08, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced the appointment of John Han, PharmD, to the role of Vice President, Medical Affairs, effective A